Ausgabe 10/2016
Inhalt (14 Artikel)
Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG
Hila Confino, Michael Schmidt, Margalit Efrati, Ilan Hochman, Viktor Umansky, Itzhak Kelson, Yona Keisari
Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer
Nasim Kheshtchin, Samaneh Arab, Maryam Ajami, Reza Mirzaei, Mahboubeh Ashourpour, Neda Mousavi, Najmeh Khosravianfar, Farhad Jadidi-Niaragh, Afshin Namdar, Farshid Noorbakhsh, Jamshid Hadjati
The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity
Mastewal Abuhay, Jason Kato, Emily Tuscano, Gustavo A. Barisone, Ranjit S. Sidhu, Robert T. O’Donnell, Joseph M. Tuscano
Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4
Marc Lopez, Abderrezak Ghidouche, Caroline Rochas, Danièle Godelaine, Javier Carrasco, Didier Colau, Gérald Hames, Félix A. Montero-Julian, Pierre G. Coulie, Daniel Olive
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases
Ileana S. Mauldin, Nolan A. Wages, Anne M. Stowman, Ena Wang, Mark E. Smolkin, Walter C. Olson, Donna H. Deacon, Kelly T. Smith, Nadedja V. Galeassi, Kimberly A. Chianese‐Bullock, Lynn T. Dengel, Francesco M. Marincola, Gina R. Petroni, David W. Mullins, Craig L. Slingluff Jr.
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases
Ileana S. Mauldin, Nolan A. Wages, Anne M. Stowman, Ena Wang, Walter C. Olson, Donna H. Deacon, Kelly T. Smith, Nadedja Galeassi, Jessica E. Teague, Mark E. Smolkin, Kimberly A. Chianese‐Bullock, Rachael A. Clark, Gina R. Petroni, Francesco M. Marincola, David W. Mullins, Craig L. Slingluff Jr.
Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy
Kohei Tada, Akiko Miyagi Maeshima, Nobuyoshi Hiraoka, Nobuhiko Yamauchi, Dai Maruyama, Sung-Won Kim, Takashi Watanabe, Naoyuki Katayama, Yuji Heike, Kensei Tobinai, Yukio Kobayashi
Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site
Shinjiro Sakamoto, Shigeru Yutani, Shigeki Shichijo, Michi Morita, Akira Yamada, Kyogo Itoh, Masanori Noguchi
A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer
Hong-Fei Zhang, Jie-Jie Qin, Peng-Fei Ren, Jian-Xiang Shi, Jun-Fen Xia, Hua Ye, Peng Wang, Chun-Hua Song, Kai-Juan Wang, Jian-Ying Zhang
4-1BB agonism: adding the accelerator to cancer immunotherapy
Cariad Chester, Siddhant Ambulkar, Holbrook E. Kohrt
Opportunities for immunotherapy in microsatellite instable colorectal cancer
Harm Westdorp, Felix L. Fennemann, Robbert D. A. Weren, Tanya M. Bisseling, Marjolijn J. L. Ligtenberg, Carl G. Figdor, Gerty Schreibelt, Nicoline Hoogerbrugge, Florian Wimmers, I. Jolanda M. de Vries
Modulation of innate immunity in the tumor microenvironment
Elena Gonzalez-Gugel, Mansi Saxena, Nina Bhardwaj
Concepts in glioma immunotherapy
Michael Platten, Lukas Bunse, Wolfgang Wick, Theresa Bunse
The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11–13, 2015
Matthias Miller, Veronika Jahndel, Sarah Kutscher, Andrea Mahr, Richard Rae, Björn-Philipp Kloke